Pulmonary fibrosis from molecular mechanisms to therapeutic interventions: lessons from post-COVID-19 patients

Pulmonary function and radiological features four months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study

(2021) Sabina A. Guler et al.   EUROPEAN RESPIRATORY JOURNAL

Serial KL-6 measurements in COVID-19 patients

(2021) Miriana d’Alessandro et al.   Internal and Emergency Medicine

Six-Month Follow-up Chest CT findings after Severe COVID-19 Pneumonia

(2021) Xiaoyu Han et al.   RADIOLOGY

Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients

(2021) Yu Zuo et al.   Scientific Reports

Significance of NETs Formation in COVID-19

(2021) Karolina Janiuk et al.   Cells

Genetic Risk Factors for Idiopathic Pulmonary Fibrosis: Insights into Immunopathogenesis

(2021) Jacob E Michalski et al.   Journal of Inflammation Research

In-hospital use of statins is associated with a reduced risk of mortality in coronavirus-2019 (COVID-19): systematic review and meta-analysis

(2021) Hikmat Permana et al.   Pharmacological Reports

Neutrophil Extracellular Traps in SARS-CoV2 Related Pneumonia in ICU Patients: The NETCOV2 Study

(2021) Mathieu Godement et al.   Frontiers in Medicine

The fight against COVID-19: Striking a balance in the renin–angiotensin system

(2021) Alexis Q. Dean et al.   DRUG DISCOVERY TODAY

TGF‑β1: Gentlemanly orchestrator in idiopathic pulmonary fibrosis (Review)

(2021) Zhimin Ye et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Post-acute COVID-19 syndrome

(2021) Ani Nalbandian et al.   NATURE MEDICINE

The characteristics and evolution of pulmonary fibrosis in COVID-19 patients as assessed by AI-assisted chest HRCT

(2021) Jia-Ni Zou et al.   PLoS One

Trajectory modeling of endothelial-to-mesenchymal transition reveals galectin-3 as a mediator in pulmonary fibrosis

(2021) Wangyue Jia et al.   Cell Death & Disease

The Duplicitous Nature of ACE2 in COVID-19 Disease

(2021) Samuel N. Heyman et al.   EBioMedicine

Angiotensin-(1-7)—A Potential Remedy for AKI: Insights Derived from the COVID-19 Pandemic

(2021) Samuel N. Heyman et al.   Journal of Clinical Medicine

Microglia extracellular vesicles: focus on molecular composition and biological function

(2021) Lorenzo Ceccarelli et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Advances in microglia cellular models: focus on extracellular vesicle production

(2021) Lorenzo Ceccarelli et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Correlation of Krebs von den Lungen-6 and fibronectin with pulmonary fibrosis in coronavirus disease 2019

(2021) Ding-Hui Peng et al.   CLINICA CHIMICA ACTA

Type 1 inflammatory endotype relates to low compliance, lung fibrosis, and severe complications in COVID-19

(2021) Takehiro Hasegawa et al.   CYTOKINE

COVID‐19 and pulmonary fibrosis: A potential role for lung epithelial cells and fibroblasts

(2021) Alison E. John et al.   IMMUNOLOGICAL REVIEWS

Pulmonary Stretch and Lung Mechanotransduction: Implications for Progression in the Fibrotic Lung

(2021) Alessandro Marchioni et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

LncRNA‐ATB regulates epithelial‐mesenchymal transition progression in pulmonary fibrosis via sponging miR‐29b‐2‐5p and miR‐34c‐3p

(2021) Qi Xu et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

SPP1 derived from silica-exposed macrophage exosomes triggers fibroblast transdifferentiation

(2021) Ruoxuan Huang et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Chronic lung diseases are associated with gene expression programs favoring SARS-CoV-2 entry and severity

(2021) Linh T. Bui et al.   Nature Communications

Reconstruction of the miR-506-Quaking axis in Idiopathic Pulmonary Fibrosis using integrative multi-source bioinformatics

(2021) Stevan D. Stojanović et al.   Scientific Reports

Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial

(2021) Jean-Claude Tardif et al.   Lancet Respiratory Medicine

Neutrophil Extracellular Traps Induce the Epithelial-Mesenchymal Transition: Implications in Post-COVID-19 Fibrosis

(2021) Laura Pandolfi et al.   Frontiers in Immunology

Fibrotic lung disease: A molecular glimpse into severe Covid-19?

(2021) Paolo Spagnolo et al.   EBioMedicine

Extracellular Vesicles in Organ Fibrosis: Mechanisms, Therapies, and Diagnostics

(2021) David R. Brigstock   Cells

Immuno-fibrotic drivers of impaired lung function in post-acute sequelae of SARS-CoV-2

(2021) Hyung J. Chun et al.   JCI Insight

Angiotensin-Converting Enzyme 2 (ACE2) in the Context of Respiratory Diseases and Its Importance in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

(2021) Enrique Ambrocio-Ortiz et al.   Pharmaceuticals

miR-21 in EVs from pulmonary epithelial cells promotes myofibroblast differentiation via glycolysis in arsenic-induced pulmonary fibrosis

(2021) Peiwen Wang et al.   ENVIRONMENTAL POLLUTION

Antibody-based therapies for idiopathic pulmonary fibrosis

(2020) Giacomo Sgalla et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

(2020) Chaolin Huang et al.   LANCET

COVID-19, ACE2, and the cardiovascular consequences

(2020) Andrew M. South et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System

(2020) Mahmoud Gheblawi et al.   CIRCULATION RESEARCH

Exosomal miR-125a-5p derived from silica-exposed macrophages induces fibroblast transdifferentiation

(2020) Di Wang et al.   ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY

Dysregulated Expression of the Nuclear Exosome Targeting Complex Component Rbm7 in Nonhematopoietic Cells Licenses the Development of Fibrosis

(2020) Kiyoharu Fukushima et al.   IMMUNITY

Targeting potential drivers of COVID-19: Neutrophil extracellular traps

(2020) Betsy J. Barnes et al.   JOURNAL OF EXPERIMENTAL MEDICINE

COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal

(2020) Hasan K. Siddiqi et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Guidelines and definitions for research on epithelial–mesenchymal transition

(2020) Jing Yang et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Cell entry mechanisms of SARS-CoV-2

(2020) Jian Shang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation

(2020) Beatriz Ballester et al.   Oncotarget

Effect of nintedanib on non‐small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review

(2020) Toshihiro Shiratori et al.   Thoracic Cancer

A pre‐ investigational new drug study of lung spheroid cell therapy for treating pulmonary fibrosis

(2020) Jhon Cores et al.   Stem Cells Translational Medicine

Pulmonary fibrosis secondary to COVID-19: a call to arms?

(2020) Paolo Spagnolo et al.   Lancet Respiratory Medicine

Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy

(2020) Peter M George et al.   Lancet Respiratory Medicine

Galectin-3: Roles in Neurodevelopment, Neuroinflammation, and Behavior

(2020) Ivan Srejovic et al.   Biomolecules

Vascular dysfunction in aged mice contributes to persistent lung fibrosis

(2020) Nunzia Caporarello et al.   AGING CELL

Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease: a comprehensive review

(2020) Miriana d’Alessandro et al.   Biomarkers in Medicine

Neutrophil Extracellular Traps (NETs) Contribute to Immunothrombosis in COVID-19 Acute Respiratory Distress Syndrome

(2020) Elizabeth A Middleton et al.   BLOOD

Telomerase treatment prevents lung profibrotic pathologies associated with physiological aging

(2020) Sergio Piñeiro-Hermida et al.   JOURNAL OF CELL BIOLOGY

Elevated MUC1 and MUC5AC mucin protein levels in airway mucus of critical ill COVID‐19 Patients

(2020) Wenju Lu et al.   JOURNAL OF MEDICAL VIROLOGY

The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections

(2020) Jatin Machhi et al.   Journal of Neuroimmune Pharmacology

COVID ‐19 acute respiratory distress syndrome ( ARDS ): clinical features and differences from typical pre‐ COVID ‐19 ARDS

(2020) Peter G Gibson et al.   MEDICAL JOURNAL OF AUSTRALIA

A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression

(2020) Samuel B. Polak et al.   MODERN PATHOLOGY

SARS-CoV-2 Pathogenesis: Imbalance in the Renin-Angiotensin System Favors Lung Fibrosis

(2020) M. Victoria Delpino et al.   Frontiers in Cellular and Infection Microbiology

Endothelial to mesenchymal transition (EndMT) and vascular remodeling in pulmonary hypertension and idiopathic pulmonary fibrosis

(2020) Archana Vijay Gaikwad et al.   Expert Review of Respiratory Medicine

Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis

(2020) Jennifer G. Wilson et al.   JCI Insight

The Interplay of the Genetic Architecture, Aging, and Environmental Factors in the Pathogenesis of Idiopathic Pulmonary Fibrosis

(2020) Annie Pardo et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis

(2020) Toby M. Maher et al.   EUROPEAN RESPIRATORY JOURNAL

First report on clinical and radiological features of COVID-19 pneumonitis in a Caucasian population: Factors predicting fibrotic evolution

(2020) Maurizio Marvisi et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

miR‐34a‐5p Attenuates EMT through targeting SMAD4 in silica‐induced pulmonary fibrosis

(2020) Yuanmeng Qi et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Complement and tissue factor–enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis

(2020) Panagiotis Skendros et al.   JOURNAL OF CLINICAL INVESTIGATION

Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID-19

(2020) Coraline Radermecker et al.   JOURNAL OF EXPERIMENTAL MEDICINE

SARS-CoV-2–triggered neutrophil extracellular traps mediate COVID-19 pathology

(2020) Flavio Protasio Veras et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Spectrum of Fibrotic Lung Diseases

(2020) Marlies Wijsenbeek et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 and COVID-19: From the Bench to the Bedside

(2020) Stefano Romagnoli et al.   PHYSIOLOGICAL REVIEWS

Two distinct immunopathological profiles in autopsy lungs of COVID-19

(2020) Ronny Nienhold et al.   Nature Communications

Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities

(2020) Peter M George et al.   Lancet Respiratory Medicine

Hyperinflammation and Fibrosis in Severe COVID-19 Patients: Galectin-3, a Target Molecule to Consider

(2020) Juan Garcia-Revilla et al.   Frontiers in Immunology

Identification of a Novel HIF-1α-αMβ2 Integrin-NET Axis in Fibrotic Interstitial Lung Disease

(2020) Akif A. Khawaja et al.   Frontiers in Immunology

Endothelial-to-Mesenchymal Transition in Cancer

(2020) Nicolas Clere et al.   Frontiers in Cell and Developmental Biology

Healing after Covid-19: Are Survivors at Risk for Development of Pulmonary Fibrosis?

(2020) Lindsay T McDonald   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Target-inhibition of Galectin-3 by Inhaled TD139 in Patients with Idiopathic Pulmonary Fibrosis

(2020) Nikhil Hirani et al.   EUROPEAN RESPIRATORY JOURNAL

Safety, tolerability, and outcomes of losartan use in patients hospitalized with SARS-CoV-2 infection: A feasibility study

(2020) Olena Bolotova et al.   PLoS One

Post covid 19 pulmonary fibrosis. Is it real threat?

(2020) Deependra Kumar Rai et al.   Indian Journal of Tuberculosis

Epithelial Injury and Dysfunction in the Pathogenesis of Idiopathic Pulmonary Fibrosis

(2019) Nichelle I. Winters et al.   AMERICAN JOURNAL OF THE MEDICAL SCIENCES

Integrating Genomics into Management of Fibrotic Interstitial Lung Disease

(2019) Ayodeji Adegunsoye et al.   CHEST

lncRNA ZEB1-AS1 promotes pulmonary fibrosis through ZEB1-mediated epithelial–mesenchymal transition by competitively binding miR-141-3p

(2019) Weibin Qian et al.   Cell Death & Disease

Translational research in pulmonary fibrosis

(2019) Susan K. Mathai et al.   Translational Research

Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study

(2019) Ganesh Raghu et al.   Lancet Respiratory Medicine

Pulmonary fibrosis: a disease of alveolar collapse and collagen deposition

(2019) Juan Snijder et al.   Expert Review of Respiratory Medicine

Rare Protein-altering Telomere-related Gene Variants in Patients with Chronic Hypersensitivity Pneumonitis

(2019) Brett Ley et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis

(2019) Christina Morse et al.   EUROPEAN RESPIRATORY JOURNAL

NETs promote ALI/ARDS inflammation by regulating alveolar macrophage polarization

(2019) Chao Song et al.   EXPERIMENTAL CELL RESEARCH

Autophagy inhibition-mediated epithelial–mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis

(2019) Charlotte Hill et al.   Cell Death & Disease

Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial

(2019) Luca Richeldi et al.   Lancet Respiratory Medicine

First‐in‐human high‐cumulative‐dose stem cell therapy in idiopathic pulmonary fibrosis with rapid lung function decline

(2019) Alexander Averyanov et al.   Stem Cells Translational Medicine

Autophagy, an important therapeutic target for pulmonary fibrosis diseases

(2019) Hong Zhao et al.   CLINICA CHIMICA ACTA

SHIP‐1, a target of miR‐155, regulates endothelial cell responses in lung fibrosis

(2019) Haiying Tang et al.   FASEB JOURNAL

Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases

(2019) Boris Hinz et al.   Nature Reviews Rheumatology

Targeting the renin–angiotensin system as novel therapeutic strategy for pulmonary diseases

(2018) Wan Shun Daniel Tan et al.   CURRENT OPINION IN PHARMACOLOGY

Elongation factor-2 kinase acts downstream of p38 MAPK to regulate proliferation, apoptosis and autophagy in human lung fibroblasts

(2018) Yanni Wang et al.   EXPERIMENTAL CELL RESEARCH

MicroRNAs in idiopathic pulmonary fibrosis, new research progress and their pathophysiological implication

(2018) Chenggui Miao et al.   EXPERIMENTAL LUNG RESEARCH

Innate lymphoid cells and fibrotic regulation

(2018) Steven Horsburgh et al.   IMMUNOLOGY LETTERS

Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications

(2018) Ralf Weiskirchen et al.   MOLECULAR ASPECTS OF MEDICINE

Matrix Stiffness: the Conductor of Organ Fibrosis

(2018) Alba Santos et al.   Current Rheumatology Reports

The A2B Adenosine Receptor Modulates the Epithelial– Mesenchymal Transition through the Balance of cAMP/PKA and MAPK/ERK Pathway Activation in Human Epithelial Lung Cells

(2018) Chiara Giacomelli et al.   Frontiers in Pharmacology

Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial

(2018) Toby M Maher et al.   Lancet Respiratory Medicine

Targeting interleukin-13 in idiopathic pulmonary fibrosis: from promising path to dead end

(2018) Marlies S. Wijsenbeek et al.   EUROPEAN RESPIRATORY JOURNAL

Idiopathic pulmonary fibrosis

(2017) Luca Richeldi et al.   LANCET

Combinatorial treatment of idiopathic pulmonary fibrosis using nanoparticles with prostaglandin E and siRNA(s)

(2017) Olga. B. Garbuzenko et al.   Nanomedicine-Nanotechnology Biology and Medicine

Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease

(2017) Ana L. Mora et al.   NATURE REVIEWS DRUG DISCOVERY

Molecular Mechanisms Modulating the Phenotype of Macrophages and Microglia

(2017) Stephanie A. Amici et al.   Frontiers in Immunology

Transcriptional firing helps to drive NETosis

(2017) Meraj A. Khan et al.   Scientific Reports

MiR-503 modulates epithelial-mesenchymal transition in silica-induced pulmonary fibrosis by targeting PI3K p85 and is sponged by lncRNA MALAT1

(2017) Weiwen Yan et al.   Scientific Reports

mTORC1 activation decreases autophagy in aging and idiopathic pulmonary fibrosis and contributes to apoptosis resistance in IPF fibroblasts

(2016) Yair Romero et al.   AGING CELL

Mechanisms of Lung Fibrosis Resolution

(2016) Stephan W. Glasser et al.   AMERICAN JOURNAL OF PATHOLOGY

EMT: 2016

(2016) M. Angela Nieto et al.   CELL

Safety and Tolerability of Alveolar Type II Cell Transplantation in Idiopathic Pulmonary Fibrosis

(2016) Anna Serrano-Mollar et al.   CHEST

Macrophages in Tissue Repair, Regeneration, and Fibrosis

(2016) Thomas A. Wynn et al.   IMMUNITY

The extracellular matrix: Tools and insights for the “omics” era

(2016) Alexandra Naba et al.   MATRIX BIOLOGY

Identification of an atypical monocyte and committed progenitor involved in fibrosis

(2016) Takashi Satoh et al.   NATURE

The development and maintenance of resident macrophages

(2016) Elisa Gomez Perdiguero et al.   NATURE IMMUNOLOGY

Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis

(2015) Fei Liu et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Nintedanib and Pirfenidone. New Antifibrotic Treatments Indicated for Idiopathic Pulmonary Fibrosis Offer Hopes and Raises Questions

(2015) Ganesh Raghu et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis

(2015) David S. Wilkes et al.   EUROPEAN RESPIRATORY JOURNAL

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis

(2015) Lutz Wollin et al.   EUROPEAN RESPIRATORY JOURNAL

Role and New Insights of Pirfenidone in Fibrotic Diseases

(2015) David Alejandro Lopez-de la Mora et al.   International Journal of Medical Sciences

Disarming Wnt

(2015) Roel Nusse   NATURE

Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study

(2015) R Gisli Jenkins et al.   Lancet Respiratory Medicine

Systemic sclerosis

(2015) Yannick Allanore et al.   Nature Reviews Disease Primers

The Lung Alveolar Lipofibroblast: An Evolutionary Strategy Against Neonatal Hyperoxic Lung Injury

(2014) Virender K. Rehan et al.   ANTIOXIDANTS & REDOX SIGNALING

IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice

(2014) Dong Li et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

(2014) Talmadge E. King et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

(2014) Luca Richeldi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Escherichia coli and Candida albicans Induced Macrophage Extracellular Trap-Like Structures with Limited Microbicidal Activity

(2014) Pan Liu et al.   PLoS One

A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis

(2014) Daniel C. Chambers et al.   RESPIROLOGY

Endothelial Cells Recruit Macrophages and Contribute to a Fibrotic Milieu in Bleomycin Lung Injury

(2013) Heather G. Leach et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis

(2013) Argyris Tzouvelekis et al.   Journal of Translational Medicine

Muc5b is required for airway defence

(2013) Michelle G. Roy et al.   NATURE

IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis

(2013) E. Hams et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Epithelial–mesenchymal transition in lung development and disease: does it exist and is it important?

(2013) Domokos Bartis et al.   THORAX

IL-15 Fosters Age-Driven Regulatory T Cell Accrual in the Face of Declining IL-2 Levels

(2013) Jana Raynor et al.   Frontiers in Immunology

Interactions Between β-Catenin and Transforming Growth Factor-β Signaling Pathways Mediate Epithelial-Mesenchymal Transition and Are Dependent on the Transcriptional Co-activator cAMP-response Element-binding Protein (CREB)-binding Protein (CBP)

(2012) Beiyun Zhou et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Pulmonary fibrosis: patterns and perpetrators

(2012) Paul W. Noble et al.   JOURNAL OF CLINICAL INVESTIGATION

Neutrophil Extracellular Traps: Double-Edged Swords of Innate Immunity

(2012) M. J. Kaplan et al.   JOURNAL OF IMMUNOLOGY

Treatment of Idiopathic Pulmonary Fibrosis with Losartan: A Pilot Project

(2012) Marisa Couluris et al.   LUNG

Infection-induced NETosis is a dynamic process involving neutrophil multitasking in vivo

(2012) Bryan G Yipp et al.   NATURE MEDICINE

Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis

(2012) Alfiya Akhmetshina et al.   Nature Communications

Regulation of Transforming Growth Factor-β1–driven Lung Fibrosis by Galectin-3

(2011) Alison C. MacKinnon et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Reversible differentiation of myofibroblasts by MyoD

(2011) Louise Hecker et al.   EXPERIMENTAL CELL RESEARCH

Eosinophil and neutrophil extracellular DNA traps in human allergic asthmatic airways

(2011) Ryszard Dworski et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

TGF-β-induced epithelial-mesenchymal transition of A549 lung adenocarcinoma cells is enhanced by pro-inflammatory cytokines derived from RAW 264.7 macrophage cells

(2011) Mikiko Kawata et al.   JOURNAL OF BIOCHEMISTRY

Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist

(2011) Roelie M Wösten-van Asperen et al.   JOURNAL OF PATHOLOGY

The distribution of immunomodulatory cells in the lungs of patients with idiopathic pulmonary fibrosis

(2011) Gerard J Nuovo et al.   MODERN PATHOLOGY

Cross Talk among TGF-  Signaling Pathways, Integrins, and the Extracellular Matrix

(2011) J. S. Munger et al.   Cold Spring Harbor Perspectives in Biology

PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis

(2010) J.S. Duffield et al.   DRUG NEWS & PERSPECTIVES

A Novel Mechanism of Rapid Nuclear Neutrophil Extracellular Trap Formation in Response to Staphylococcus aureus

(2010) F. H. Pilsczek et al.   JOURNAL OF IMMUNOLOGY

Serum Amyloid P Therapeutically Attenuates Murine Bleomycin-Induced Pulmonary Fibrosis via Its Effects on Macrophages

(2010) Lynne A. Murray et al.   PLoS One

Endothelial–Mesenchymal Transition in Bleomycin-Induced Pulmonary Fibrosis

(2009) Naozumi Hashimoto et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis

(2008) Xiaopeng Li et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy

(2008) F. Hilberg et al.   CANCER RESEARCH

Functional Wnt Signaling Is Increased in Idiopathic Pulmonary Fibrosis

(2008) Melanie Königshoff et al.   PLoS One